33 research outputs found
UV Absorption Lines from High-Velocity Gas in the Vela Supernova Remnant: New insights from STIS Echelle Observations of HD72089
The star HD72089 is located behind the Vela supernova remnant and shows a
complex array of high and low velocity interstellar absorption features arising
from shocked clouds. A spectrum of this star was recorded over the wavelength
range 1196.4 to 1397.2 Angstroms at a resolving power lambda/Delta lambda =
110,000 and signal-to-noise ratio of 32 by STIS on the Hubble Space Telescope.
We have identified 7 narrow components of C I and have measured their relative
populations in excited fine-structure levels. Broader features at heliocentric
velocities ranging from -70 to +130 km/s are seen in C II, N I, O I, Si II, S
II and Ni II. In the high-velocity components, the unusually low abundances of
N I and O I, relative to S II and Si II, suggest that these elements may be
preferentially ionized to higher stages by radiation from hot gas immediately
behind the shock fronts.Comment: 11 pages, 2 figures, Latex. Submitted for the special HST ERO issue
of the Astrophysical Journal Letter
Domestic Poultry and SARS Coronavirus, Southern China
SARS coronavirus injected intratracheally into chickens, turkeys, geese, ducks, and quail, or into the allantoic sac of their embryonating eggs, failed to cause disease or replicate. This finding suggests that domestic poultry were unlikely to have been the reservoir, or associated with dissemination, of SARS coronavirus in the animal markets of southern China
Interlaboratory study for coral Sr/Ca and other element/Ca ratio measurements
The Sr/Ca ratio of coral aragonite is used to reconstruct past sea surface temperature (SST). Twentyone
laboratories took part in an interlaboratory study of coral Sr/Ca measurements. Results show
interlaboratory bias can be significant, and in the extreme case could result in a range in SST estimates of
7°C. However, most of the data fall within a narrower range and the Porites coral reference material JCp-
1 is now characterized well enough to have a certified Sr/Ca value of 8.838 mmol/mol with an expanded
uncertainty of 0.089 mmol/mol following International Association of Geoanalysts (IAG) guidelines.
This uncertainty, at the 95% confidence level, equates to 1.5°C for SST estimates using Porites, so is
approaching fitness for purpose. The comparable median within laboratory error is <0.5°C. This
difference in uncertainties illustrates the interlaboratory bias component that should be reduced through
the use of reference materials like the JCp-1. There are many potential sources contributing to biases in
comparative methods but traces of Sr in Ca standards and uncertainties in reference solution composition
can account for half of the combined uncertainty. Consensus values that fulfil the requirements to be
certified values were also obtained for Mg/Ca in JCp-1 and for Sr/Ca and Mg/Ca ratios in the JCt-1 giant
clam reference material. Reference values with variable fitness for purpose have also been obtained for
Li/Ca, B/Ca, Ba/Ca, and U/Ca in both reference materials. In future, studies reporting coral element/Ca
data should also report the average value obtained for a reference material such as the JCp-1
Finishing the euchromatic sequence of the human genome
The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead
Abstract CT191: Interim results from CLASSICAL-Lung, phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC
Despite progress of immune checkpoint therapies, many cases of non-small cell lung cancer (NSCLC) are refractory or acquire resistance to current therapies. Antibody blockade of semaphorin 4D (SEMA4D, CD100) can overcome resistance mechanisms of immune exclusion and myeloid suppression. Importantly, combinations of anti-SEMA4D with various immunotherapies enhanced T cell infiltration and activity, leading to durable tumor regression in preclinical models. Pepinemab (VX15/2503) is a first-in-class humanized monoclonal antibody targeting SEMA4D. The CLASSICAL-Lung clinical trial tests the combination of pepinemab with avelumab to couple immune activation via checkpoint inhibition with beneficial modifications of the tumor immune microenvironment via pepinemab. Here, we present interim results of the Phase 2 portion of the CLASSICAL-Lung study. This phase 1b/2, open label, single arm, first-in-human combination study is designed to evaluate the safety, tolerability and efficacy of pepinemab in combination with avelumab in 62 subjects with advanced stage (IIIB/IV) NSCLC, including immunotherapy-naïve (ION) patients and patients whose tumors progressed during or following immunotherapy (IOF). Dose escalation was successfully completed, presented previously, and no concerning safety signals have been identified to date. Among 29 evaluable IOF patients, 2 experienced confirmed partial response (PR) with 66% and 52% tumor reduction following acquired resistance to prior treatment with pembrolizumab, 15 additional patients experienced stable disease (SD), and at least 7 patients had durable clinical benefit of ≥ 23 weeks. Among 21 evaluable ION patients, 5 experienced PR, and 3 patients had clinical benefit ≥ 1 year. The disease control rate was 81%. Analysis of pre- and on-treatment biopsies demonstrated increased CD8+ T cell density correlating with response, with reduction or elimination of tumor in 10/11 biopsies from subjects with PR or SD. It was notable that 79% of patients who experienced PR or SD were reported to have tumors with negative or low PD-L1 expression. Enrollment is complete and this interim analysis suggest the combination of pepinemab plus avelumab is well tolerated and shows initial clinical signals of antitumor activity. Updated clinical response data, as well as additional immunophenotyping of both inflammatory and suppressive myeloid cells will be presented